SYGNIS AG: SYGNIS introduces 2view unique Western blot detection technology (news with additional features)

DGAP-News: SYGNIS AG / Key word(s): Product Launch

09.05.2018 / 07:30

The issuer is solely responsible for the content of this announcement.


PRESS RELEASE
09 May 2018

 

SYGNIS introduces 2view unique Western blot detection technology

Offers two modes of detection from a single antibody

– Fast visible detection of analytes at nanogram level

– Enhanced chemi-luminescence detection down to picogram level

– Easy to use with a single incubation

Heidelberg, Germany and Cambridge, UK, 09 May 2018 SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced the introduction of 2view(TM), a unique detection method optimised for Western blotting, under its Expedeon brand name.

2view(TM) is an innovative double labeled secondary antibody that enables extended detection within the widely used Western blot application. The product consists of a ternary complex developed using the company’s world leading InnovaCoat(R) and Lightning-Link(R) technology. 2view(TM) secondary antibodies are labeled simultaneously with a visible (InnovaCoat(R) GOLD nanoparticles) and proprietary chemi-luminescent enzymatic detection system. The gold nanoparticles enable fast visible detection at nanogram level whereas the enzymatic detection mechanism enhances sensitivity down to picogram levels of protein.

Expedeon currently offers a wide range of products within the Western blot market, expected to reach $730.7 million by 2021, including its InstantBlue(TM) staining and Lightning-Link(R) primary antibody labeling technologies. The launch of 2view(TM) further opens up the Western blot market for the company, as well as providing access to the secondary antibody market which was estimated at $400 million in 2017, as well as complementing the company’s range of secondary reagents. Expedeon will market this product through its direct sales and distribution channels and will also be looking to exploit the technology through OEM and licensing opportunities with antibody manufacturers.

Dr. Nick Gee, Chief Technology Officer, SYGNIS, said: “We are highly committed to expanding our range of cutting-edge tools and services to simplify processes and increase efficiency in the lab. The introduction of the 2view(TM) Western blot detection technology will make a significant difference to many researchers.”

SYGNIS subsidiaries Innova Biosciences, Expedeon Holdings, and C.B.S. Scientific united as Expedeon on 1 March 2018. The corporate rebranding followed the acquisition of Innova Biosciences by SYGNIS AG in June 2017. SYGNIS AG continues to serve as the parent company and legal entity. The combined Expedeon product portfolio now comprises a wide range of complementary products and services to support the genomic, proteomic and immunology markets. The combined product offering is accessible via the newly launched website www.expedeon.com.

/
For a high resolution image please contact Zyme Communications
For further information, please contact:

SYGNIS AG
Dr. Heikki Lanckriet
CEO/CSO
Phone: +44 1223 873 364
Email: heikki.lanckriet@sygnis.com

MC Services AG (Investor Relations and International Media Relations)
Dr. Claudia Gutjahr-Löser
Managing Director
Phone: +49 89 210228 0
Email: sygnis@mc-services.eu

Zyme Communications (Trade and UK Media Relations)
Katie Odgaard
Tel: +44 (0)7787 502 947
Email: katie.odgaard@zymecommunications.com

About SYGNIS AG: www.sygnis.com
SYGNIS develops and commercialises value-added, easy-to-use, reliable products for genomics and proteomics research based on its proprietary technologies, offering a wide range of solutions that address key challenges in molecular biology. With applications spanning the entire molecular biology workflow, the Group’s cutting-edge offerings include easy-to-use off-the-shelf products as well as custom services, supporting scientists from academia through to commercial manufacturing. SYGNIS’ products are sold through a direct sales force and several distribution partners in Europe, the USA and Asia. SYGNIS AG has offices in Germany, Spain, UK, USA and Singapore which trade under the Expedeon brand. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: LIO1; ISIN: DE000A1RFM03).

### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###


Additional features:

Document: http://n.eqs.com/c/fncls.ssp?u=CSOHHWIWAX
Document title: 2View_Eng


09.05.2018 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: SYGNIS AG
Waldhofer Str. 104
69123 Heidelberg
Germany
Phone: +49 (0) 6221 3540 125
Fax: +49 (0) 6221 3540 127
E-mail: investors@sygnis.com
Internet: www.sygnis.com
ISIN: DE000A1RFM03
WKN: A1RFM0
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange

 
End of News DGAP News Service

show this